We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (n = 50 PP; n = 1 RLAI) enrolled; 35 completed the study. All-cause and medicationrelated discontinuation was 30% and 9% over 6 months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL.
Introduction
As the number of long-acting injectable antipsychotic medication options increases, the need has grown for commensurate data pertaining to safety and outcomes when switching between different LAIs (Correll et al., 2016) . In particular, clinicians may hesitate to recommend a medication change because they are unsure about the relative safety of switching a patient from one long-acting injectable antipsychotic medication based on suboptimal response to another long-acting injectable with a different pharmacodynamic profile.
Paliperidone palmitate (PP) and risperidone LAI (RLAI) are widely used atypical long-acting injectable antipsychotics. Although PP and RLAI are effective, as with any first-line antipsychotics, PP and RLAI will not be fully effective or tolerable for all patients, and clinicians may consider switching to another LAI with a different pharmacodynamic profile. Aripiprazole lauroxil (AL), a prodrug of the atypical antipsychotic aripiprazole, is an long-acting injectable for the treatment of adults with schizophrenia (Citrome, 2016; Cruz, 2016) . The objective of this study was to assess the clinical outcomes and safety of switching patients who continue to experience persistent symptoms or tolerability problems from PP/RLAI to AL.
Experimental methods

Study design
This was a prospective, 6-month, open-label study in patients with schizophrenia who were clinically stable on PP/RLAI but who continued to experience persistent symptoms or tolerability problems that may be addressed by a change in antipsychotic medication (ClinicalTrials.gov, NCT02634320; Fig. 1 ). The primary objective was to explore the treatment effectiveness, safety, and tolerability of AL in patients who had switched from PP/RLAI.
The first AL dose and subsequent dose adjustments were according to the investigator's clinical judgment. Stepwise dose decreases were allowed for tolerability, while increases were allowed for efficacy or up-titration. Most dose changes were performed after the second injection in accordance with protocol recommendations. Oral antipsychotics prescribed and administered at therapeutic levels before the start of the study could be continued at the investigator's discretion.
Patients
Eligible participants were from 18 to 65 years of age with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (American Psychiatric Association, 2013) . Patients had to have been clinically stable for ≥2 months (no hospitalizations and Brief Psychiatric Rating Scale [BPRS] score ≥30 and ≤45), and had to have been treated with ≥3 doses of PP/RLAI before screening, with no antipsychotic medication regimen change for 4 weeks before day 1.
Outcome measures and assessments
A composite measure of treatment effectiveness was "all-cause discontinuation" (defined as discontinuation for any reason) (Lieberman et al., 2005) and "medication-related discontinuation" (defined as discontinuations specifically attributed to limitations of AL [i.e., due to lack of efficacy or an adverse event (AE)]).
Clinical symptoms were assessed using the Clinical Global Impressions-Severity (CGI-S; 7-point scale ranging from 1 [normal] to 7 [among the most extremely ill patients] (Guy, 1976) ) and BPRS scores (18 items on which clinicians rate patients' symptoms on a 7-point scale (Overall and Gorham, 1962) ) at baseline and monthly thereafter. Safety and tolerability was assessed by monitoring AEs.
Statistical analysis
The initial planned enrollment was 90 patients but the final enrollment included 51 patients because of enrollment challenges. Summary statistics (number, mean, and SD for continuous variables; number and percentage of patients in each category for categorical variables) are provided for variables evaluated.
Patient disposition and baseline demographics were summarized. Patients were categorized into three groups-persistent positive symptoms, persistent negative symptoms, and tolerability concerns-based on the primary reasons for switching at the time of study enrollment. Differences in baseline demographics and characteristics among the three groups were compared using analysis of variance for continuous outcomes and chi-square test for categorical outcomes.
Kaplan-Meier survival curves were used to estimate the time to discontinuation of treatment (all-cause and medication-related) in all enrolled patients. CGI-S and BPRS scores and change from baseline at each visit were summarized by switch group and overall using descriptive statistics. A one-sample t-test at each visit and at the end of the treatment period for all patients was conducted to determine whether changes from baseline were statistically significant. Changes in CGI-S and BPRS scores were also analyzed using a mixedeffects model for repeated measures (MMRM) for patients previously administered PP (n = 50) (excluding one patient previously treated with RLAI). These analyses included visits as factors and baseline values as covariates. The unstructured variance and covariance matrix was used to model within-subject variability. Least squares mean change from baseline and SE at each visit were reported and were compared for statistical significance on a 2-sided alpha level of 0.05.
Results
Patient disposition and baseline demographics
Fifty-one patients enrolled in the study and switched to AL from PP (n = 50) and RLAI (n = 1). Mean age was 40.6 years and most (72.5%) were men (Table 1 ). Primary reasons for switching patients from previous LAI to AL included persistent positive symptoms (n = 34; 66.7%), ongoing tolerability concerns (n = 9; 17.6%), and persistent negative symptoms (n = 8; 15.7%) (Fig. 2) . Baseline characteristics were comparable between subgroups (Table 1) , except for lower baseline CGI-S scores in the group who switched for tolerability reasons. No statistically significant differences in baseline demographics and characteristics among the three groups except for CGI-S score (p = 0.004).
Patient retention and time to treatment discontinuation
Of 51 patients, 68.6% (n = 35) completed all study follow-up visits over 6 months, and 16 (31.4%) discontinued before the final assessment. Of the 16 early discontinuations, the mean time between the last AL injection and end of study assessment was 39.9 days (SD 21.7; median, 36). The discontinuation rate attributed to lack of efficacy was 3.9% (n = 2) and to any AE was 3.9% (n = 2). Other reasons for discontinuation not attributed to either efficacy or tolerability included patient decision (9.8%; n = 5), loss to follow-up (5.9%; n = 3), other (5.9%; n = 3), and protocol deviation (2.0%; n = 1). The completion rate by initial reason for switching to AL was 88.9% (8/9) when switching for tolerability, 65% (22/34) for switching related to positive symptoms, and 62% (5/8) when switching for negative symptoms.
Kaplan-Meier plots of time to all-cause and medication-related discontinuations are shown in Fig. 3 . The estimated probability of allcause discontinuation at 6 months was 30.4% and of medicationrelated discontinuation was 9.2%.
Clinical symptoms and outcomes
CGI-S
Statistically significant improvements in CGI-S score were observed at month 3 and through the end of the treatment period using both onesample t-test (Fig. 4a) .
BPRS
The mean (SD) BPRS score decreased from 37.6 (5.7) to 32.7 (6.7) after 6 months of AL treatment (mean change [SD] −4.9 [8.5]; p = 0.002) ( Table 2 ). Statistically significant improvements in BPRS scores were also observed at month 6 using MMRM (mean change [SE] −4.0 [1.3]; p b 0.01) (Fig. 4b) .
Safety and tolerability
AEs were reported in 41.2% (n = 21) of patients; the most common were psychotic disorder (7.8%; n = 4), anxiety (5.9%; n = 3), and suicidal ideation (5.9%; n = 3) (Table 3) . Nine patients (17.6%) had AEs Fig. 2 . Primary reason for switch. During screening, reasons for changing antipsychotic medication were recorded by the investigator using a checkbox questionnaire. Fig. 3 . Kaplan-Meier plot of time to medication-related and all-cause discontinuation. Discontinuation was defined as last study assessment, with a median of 36 days between the final AL injection and the discontinuation date. *Medication-related discontinuation was defined as any occurrence of discontinuation because of lack of efficacy or an adverse event.
considered to be study drug-related. Most AEs (76.2%; n = 16) were mild or moderate. Two patients discontinued the study because of AEs (one due to psychotic disorder, one due to gynecomastia). Serious AEs were reported in five (9.8%) patients, none of which were related to the study drug, and no deaths were reported during the study. One patient experienced two episodes of akathisia, one mild and one moderate, which resolved spontaneously; no other extrapyramidal symptom-related AEs were reported.
Discussion
To our knowledge, this is the first prospective study of the safety of switching from other long-acting injectable antipsychotics to AL. More than two-thirds of patients completed the full 6-month course of AL and b10% discontinued treatment for medication-related reasons (lack of efficacy or an AE). The 6-month flexible AL regimen was associated with statistically significant improvements in clinical symptoms, as measured by the CGI-S and BPRS. As is the case with open-label switch studies, symptom improvement cannot be used to assess the relative efficacy of antipsychotics before and after switching because of selection of patients who, by definition, had efficacy or tolerability problems with the pre-switch medication.
In general, the switch from PP or RLAI to AL was well tolerated, with an AE profile consistent with the known safety profile of AL (Meltzer et al., 2015) .
The strengths of this study are that it approximated clinical practice by using minimal inclusion/exclusion criteria, permitted the use of concomitant medications (including valproate and oral antipsychotics), and allowed flexible dosing based on the needs of patients. This is one of the few switching studies not limited by unknown adherence to Baseline is defined as the last non-missing value on or before the first dose of study drug. The p-value is for comparison of the mean change with 0 at each visit using a one-sample t-test. The p-value is provided for the "all patients" group only because of the small number in each group. AL = aripiprazole lauroxil; BPRS = Brief Psychiatric Rating Scale; CGI-S = Clinical Global Impressions-Severity. In summary, this study demonstrates the feasibility of switching patients with persistent symptoms or tolerability issues from PP or RLAI to AL. The clinical benefit observed in the study occurred irrespective of the investigator-determined AL dosing regimen, suggesting that clinicians have the flexibility to select the regimen that is most compatible with the individual needs of their patients. Psychotic disorder 4 (7.8) Anxiety 3 (5.9) Suicidal ideation 3 (5.9) Diarrhea 2 (3.9) Hypertension 2 (3.9) Insomnia 2 (3.9) Pyrexia 2 (3.9) Weight decreased 2 (3.9) Weight increased 2 (3.9) AE = adverse event; SAE = serious adverse event. a SAEs were as follows: psychotic disorder (n = 2), suicidal ideation (n = 2), chronic obstructive pulmonary disease (n = 1).
